Calcimimetic agents: Review and perspectives

Kidney International, Supplement

Volumn 63, Issue 85, 2003, Pages

  Ureña, Pablo ^a   Frazão, João M ^b  

^a Clinique de l'Orangerie Aubervilliers   (France)

^b NONE

Author keywords

Calcimimetics; Calcium sensing receptor; Hypocalcemia; Parathyroid hormone; Renal osteodystrophy; Review; Secondary hyperparathyroidism

Indexed keywords

ALUMINUM; BARIUM; CADMIUM; CALCIUM; CALCIUM CHANNEL STIMULATING AGENT; CALCIUM PHOSPHATE; CALCIUM SENSING RECEPTOR; CATION; CINACALCET; COBALT; GADOLINIUM; GENTAMICIN; HEXACYCLINE; IRON; KANAMYCIN B; KRN 568; LANTHANUM; LEAD; MAGNESIUM; N [3 (2 CHLOROPHENYL)PROPYL] 1 (3 METHOXYPHENYL)ETHYLAMINE; NEOMYCIN; NICKEL; NPS R567; NPS S567; NPS S568; PARATHYROID HORMONE; PHOSPHORUS; POLYAMINE; STREPTOMYCIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BONE TURNOVER; CALCIUM BLOOD LEVEL; CALCIUM EXCRETION; CALCIUM HOMEOSTASIS; CLINICAL TRIAL; CONFERENCE PAPER; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG SAFETY; EXTRACELLULAR CALCIUM; FEMALE; HORMONE RELEASE; HUMAN; HYPERCALCEMIA; HYPERPARATHYROIDISM; HYPERPHOSPHATEMIA; HYPOPARATHYROIDISM; MOLECULAR CLONING; NONHUMAN; PARATHYROID HORMONE RELEASE; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN FUNCTION; SECONDARY HYPERPARATHYROIDISM; UREMIA;

EID: 0037512520     PISSN: 00986577     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.63.s85.22.x     Document Type: Conference Paper

References (31)

1. HRUSKA K: New concepts in renal osteodystrophy. Nephrol Dial Transplant 13:2755-2760, 1998
2. HERCZ G, PEI Y, GREENWOOD C, et al: Aplastic osteodystrophy without aluminum: The role of "suppressed" parathyroid function. Kidney Int 44:860-866, 1993
3. DEVERNEJOUL MC, KUNTZ D, MIRAVET L, et al: Bone histomorphometry in hemodialysed patients. Metab Bone Dis Rel Res 3:175-179, 1981
4. GAGNÉ ER, UREÑA P, LEITE-SILVA S, et al: Short and long-term efficacy of total parathyroidectomy with immediate autografting compared with subtotal parathyroidectomy in hemodialysis patients. J Am Soc Nephrol 3:1008-1017, 1992
5. GOODMAN W, GOLDIN J, KUIZON B, et al: Coronary artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 342:1478-1483, 2000
6. BLOCK G, HULBERT-SHEARON T, LEVIN N, PORT F: Association of serum phosphorus and calcium x phosphorus product with mortality risk in chronic hemodialysis patients: A national study. Am J Kidney Dis 31:607-617, 1998
7. FINE A, ZACHARIAS J: Calciphylaxis is usually non-ulcerating: Risk factors, outcome and therapy. Kidney Int 61:2210-2217, 2002
8. BROWN E, GAMBA G, RICCARDI D, et al: Cloning and characterization of an extracellular Ca2+-sensing receptor from bovine parathyroid. Nature 366:575-580, 1993
9. BROWN E, POLLAK M, SEIDMAN C, et al: Calcium-ion-sensing cell-surface receptors. N Engl J Med 333:234-240, 1995
10. NEMETH E, FOX J: Calcimimetic compounds: A direct approach to controlling plasma levels of parathyroid hormone in hyperparathyroidism. Trends Endocrinol Metab 10:66-71, 1999
11. FOX J, LOWE S, PETTY B, NEMETH E: NPS R-568: A type II calcimimetic compound that acts on parathyroid cell calcium receptor of rats to reduce plasma levels of parathyroid hormone and calcium. J Pharmacol Exp Ther 290:473-479, 1999
12. BAI M: Structure and function of the extracellular calcium-sensing receptors (review). Int J Mol Med 4:115-125, 1999
13. BROWN E, POLLAK M, HEBERT S: The extracellular calcium-sensing cell-surface receptor: Its role in health and disease. Annu Rev Med 49:15-29, 1998
14. PEARCE S: Extracellular "calcistat" in health and disease. Lancet 353:82-83, 1999
15. HANDLOGTEN M, HUANG C, SHIRAISHI N, et al: The Ca2+-sensing receptor activates cytosolic phospholipase A(2) via a G(Q) alpha-dependent ERK-independent pathway. J Biol Chem 276:13941-13948, 2001
16. GOODMAN W, FRAZAO JM, GOODKIN D, et al: A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism. Kidney Int 58:436-445, 2000
17. NEMETH E, STEFFEY M, HAMMERLAND L, et al: Calcimimetics with potent and selective activity on the parathyroid calcium receptor. Proc Nat Acad Sci 95:4040-4045, 1998
18. RAY K, NORTHUP J: Evidence for distinct cation and calcimimetic compound (NPS 568) recognition domains in the transmembrane regions of the human calcium receptor. J Biol Chem 277:18908-18913, 2002
19. FOX J, LOWE S, CONKLIN R, NEMETH E: The calcimimetic NPS R-568 decreases plasma PTH in rats with mild and severe renal or dietary secondary hyperparathyroidism. Endocrine 10:97-103, 1999
20. FOX J, LOWE S, CONKLIN R, et al: Calcimimetic compound NPS R-568 stimulates calcitonin secretion but selectively targets parathyroid gland Ca(2+) receptor in rats. J Pharmacol Exp Ther 290:480-486, 1999
21. WADA M, FURUYA Y, SAKIYAMA J, et al: The calcimimetic compound NPS R-568 suppresses parathyroid cell proliferation in rats with renal insufficiency. J Clin Invest 100:2977-2983, 1997
22. WADA M, NAGANO N, FURUYA Y, et al: Calcimimetic NPS R-568 prevents parathyroid hyperplasia in rats with severe secondary hyperparathyroidism. Kidney Int 57:50-58, 2000
23. CHIN J, MILLER S, WADA M, et al: Activation of the calcium receptor by a calcimimetic compound halts the progression of secondary hyperparathyroidism in uremic rats. J Am Soc Nephrol 11:903-911, 2000
24. WADA M, ISHII H, FURUYA Y, et al: NPS R-568 halts or reverses osteitis fibrosa in uremic rats. Kidney Int 53:448-453, 1998
25. ISHII H, WADA M, FURUYA Y, et al: Daily intermittent decreases in serum levels of parathyroid hormone have an anabolic-like action on the bones of uremic rats with low-turnover bone and osteomalacia. Bone 26:175-182, 2000
26. COBURN J, MAUNG H: Calcimimetic agents and the calcium-sensing receptor. Curr Opin Nephrol Hypertens 9:123-132, 2000
27. LALONDE RL, GAUDREAULT J, KARHU DA, MARRIOTT TB: Mixed-effects modeling of the pharmaco-dynamic response to the calcimimetic agent R-568. Clin Pharmacol Ther 65:40-49, 1999
28. SILVERBERG SI, BONE H, MARRIOT T, et al: Short-term inhibition of parathyroid hormone secretion by a calcium receptor agonist in primary hyperparathyroidism. N Engl J Med 337:1506-1510, 1997
29. COLLINS MT, SKARULIS MC, BILEZIKIAN JP, et al: Treatment of hypercalcemia secondary to parathyroid carcinoma with a novel calcimimetic agent. J Clin Endocrinol Metab 83:1083-1088, 1998
30. ANTONSEN J, SHERRARD D, ANDRESS D: A calcimimetic agent acutely suppresses parathyroid hormone levels in patients with chronic renal failure. Kidney Int 53:223-227, 1998
31. GOODMAN W, HLADIK GA, TURNER SA, et al: The calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. J Am Soc Nephrol 13:1017-1024, 2002